If one antibody won’t work, how about three? Or three in one? - aidsmap

If one antibody won’t work, how about three? Or three in one?  aidsmap

Elimination of HIV-1-infected cells by broadly neutralizing antibodies - Nature.com

Elimination of HIV-1-infected cells by broadly neutralizing antibodies  Nature.com

Antibody-like proteins that capture and neutralize SARS-CoV-2 - Science

Antibody-like proteins that capture and neutralize SARS-CoV-2  Science

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination - The L...

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination  The Lancet

Robotic neutralizing antibody testing system transforms COVID immunity tracking - ABB

Robotic neutralizing antibody testing system transforms COVID immunity tracking  ABB

A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in n...

A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant  Nature.com

HIV vaccine that generates broadly neutralising antibodies passes first safety and proof-of-conce...

HIV vaccine that generates broadly neutralising antibodies passes first safety and proof-of-concept study in humans  aidsmap

Broadly neutralising antibodies may be partners for long-acting antiretrovirals - aidsmap

Broadly neutralising antibodies may be partners for long-acting antiretrovirals  aidsmap

Singapore team's Covid-19 neutralising antibody test kit is first to get US FDA approval - The St...

Singapore team's Covid-19 neutralising antibody test kit is first to get US FDA approval  The Straits Times

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel? - aidsmap

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel?  aidsmap

Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option - aidsmap

Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option  aidsmap